The Genecept™ Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and uses a proprietary panel of biomarker tests, providing an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, PTSD, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/the-science-behind-the-test.

 

 

 

About Genomind

 

Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.

​

 

 

Advancing Personalized Medicine in Neuropsychiatry

​

​

Scientists have discovered specific genetic variations that modify the body’s response to certain drugs and therapies. By identifying these variations, clinicians can design a treatment plan optimized for an individual patient. This new development is known as “personalized medicine”.

 

Personalized medicine has the potential to both increase treatment effectiveness and lower costs across a wide range of medical specialties. Applying this technology to mental health provides a more rational and personalized approach to treatment.

 

 

 

Mental Illness: The Startling Facts

 

Over a quarter of U.S. adults are diagnosed with one or more mental disorders.

• By 2020, major depressive illness will be the leading cause of disability in the world for women and children.

• 2.6% of the U.S. adult population has bipolar disorder. Only about half are receiving treatment.

• 51 million people worldwide suffer from schizophrenia. The earlier the disease is diagnosed and treated, the better the outcome.

• 1 in 88 children has been diagnosed with an autism spectrum disorder. The prevalence of this disorder has increased 78% from 2002.

 

GeneSight

 

The test, known as GeneSight, analyzes eight genes of a person’s DNA from a simple check swab to determine what that individual’s likely response and exposure level, or rate of metabolism, will be to 38 different anti-depressants and anti-psychotics.

 

GeneSight is a genetic test that helps healthcare providers take a personalized approach to prescribing medicine for patients.  Because genes influence the way a person’s body responds to specific medications, the medications may not work the same for everyone. Using DNA gathered with a simple cheek swab, GeneSight analyzes a patient’s genes and provides individualized information to help healthcare providers select medications that better match their patient’s genes. Multiple clinical studies have shown that when clinicians used GeneSight to help guide treatment decisions, patients were up to twice as likely to respond to the selected medication compared to standard of care.